<DOC>
	<DOC>NCT00490360</DOC>
	<brief_summary>Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head</brief_title>
	<detailed_description>Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After restaging excludes disease progression, a standard Whipple procedure is performed. Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30. - Trial with medicinal product</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criteria: Age &gt; 18 years Histologically or cytologically confirmed resectable ductal adenocarcinoma of the pancreatic head WHOperformance status 02 Written informed consent Discussion in an intrdisciplinary conference Exclusion criteria: Insufficient renal function (calculated creatinin clearance &lt; 60ml(min) Insufficient hematologic function (neutrophil count &lt;1'000/ul, platelets &lt; 100'000/ul) Uncorrectable coagulopathy Severe cholestasis (bilirubin &gt;100mmol/l) Distant metastases in liver, lungs or other organs Peritoneal carcinomatosis Unresectable tumor (s. 4.2.) Contraindication for Whipple procedure Uncontrolled infection Neurotphil count &gt; Â°2 Estimated life experience &lt; 6 months HIV Infection Severe medical or psychatric comorbidities which interefere with the participation in this trial or the informed consent Female patients in childbearing age without adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>